• Molecular Partners flagged a US Phase 1/2a trial of DLL3-targeting radiotherapy MP0712, with patient dosing underway in the first cohort.
• Initial clinical results have not been released; first data are expected later in 2026.
• Trial aims to establish a recommended dose, with early evaluation of safety and anti-tumor activity in small cell lung cancer and other DLL3-expressing tumors.
• Earlier patient imaging from a South Africa compassionate-use program indicated tumor targeting, supporting continued clinical development.
• Trial-in-progress updates are scheduled for presentation at ASCO on May 30, 2026, then SNMMI on June 2, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003818), on June 01, 2026, and is solely responsible for the information contained therein.